SOURCE: Adgero Biopharmaceuticals, Inc.

Adgero Biopharmaceuticals, Inc.

September 19, 2016 07:30 ET

Adgero Biopharmaceuticals to Present at 2016 Aegis Growth Conference on September 21, 2016

Presentation With Live Webcast on Wednesday, September 21st at 2:00 PM ET

PRINCETON, NJ--(Marketwired - September 19, 2016) - Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, today announced that it will present at the 2016 Aegis Growth Conference on Wednesday, September 21, 2016 at 2:00 p.m. PT in Las Vegas, NV.

Frank G. Pilkiewicz, Ph.D., Chief Executive Officer, will present an overview of the Company's lead product candidate, REM-001 Therapy, which has demonstrated promising safety and efficacy results in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC"), the majority of whom have failed radiation therapy.

Dr. Pilkiewicz will also review the strategy for clinical and regulatory advancement of REM-001 Therapy, including anticipated filings for Orphan Drug and Breakthrough Therapy designations expected in 2016. Additionally, he will discuss Adgero's growth strategy focused on potential pipeline expansion into additional cutaneous cancer indications.

A live webcast of the presentation will be available on the Company's website at www.AdgeroBiopharm.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.

About Adgero
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous (skin surface) metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

For more information, please visit www.AdgeroBiopharm.com.

Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact Information